XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.80

-0.1%

Nov 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (7611)	10/31/1998 9:39:00 AM
From: Bluegreen	Read Replies (1) of 17367

To: Rocketman (5854 ) From: Bluegreen Saturday, Oct 31 1998 12:37AM ET Reply # of 5856 Rman, you are probably old enough to remember how clinicians pushed the envelope with Beta blockers and Calcium channel blockers. Talk about off label usage! Clinicians worldwide are frothing at the mouth to push the envelope with the BPI molecule in the same fashion in my opinion. You think clinicians are concerned about official FDA indication? Especially when they are armed with BPI's safety profile? I would also think expense would probably be no more in today's dollar to treat than hospital emergency condition administration of Calcium channel blockers in their heyday. Sepsis, oh yeah, but what about synergistic effects when combined with antibiotics? How much of that decrease in mortality in Phase II Meningo. was due to rapid clearance of LPS or synergy with antibiotics administered? If you will take a quick look at collaborations being done worldwide just on BPI molecule you might be surprised. November issue of Discover magazine has some excellent reading on antimicrobial peptides and reasons why they are very difficult to get as Harmon was saying "high flying."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next